explore -WSS

explore

author：Wikipedia 2025-09-05 09:17:04 - browse：9

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： STAT Readout Newsletter: Today in biotech, life science news

focus

knowledge

WSS

Cancer cells are shown to suck energy source from immune cells

CDC's new outbreak response network to include Northeastern

Senators: Long

Second xenotransplant done with gene

European regulators recommend Amylyx's ALS drug be rejected

Changes to biosimilar regulatory framework must prioritize patients

hotspot

explore

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Takeaways from AdvaMed, the largest medical devices conference

Tori Bowie and the unacceptable rates of Black maternal death

EpiPen alternative approval delay highlights citizen petition issue

Drug repurposing or repositioning? The language matters

Life sciences deals on track to hit lowest point since 2017

Wildfire smoke exposes gaps in outdoor worker protections

Researchers CRISPR chickens in bid to protect them from bird flu

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Peter Marks talks Operation Warp Speed for Rare Diseases

focus

There’s no way to know how good AI health technologies are

EpiPen alternative approval delay highlights citizen petition issue

Microbiome research is starting to find links to chronic diseases

Eight reasons why you should get an updated Covid vaccine

CDC advisers recommend seasonal use of Pfizer RSV shot

What the Wegovy shortage looks like for doctors — and for patients

focus

knowledge

entertainment

leisure time